3rd Annual Experimental Therapeutics in Oncology: The Road to Personalized Medicine

Los Angeles, California
Friday, November 07, 2014

3rd Annual Experimental Therapeutics in Oncology: The Road to Personalized Medicine
Friday, November 07, 2014 2:00 PM -
Saturday, November 08, 2014 4:50 PM (Pacific Time)

Cedars-Sinai Medical Center
Harvey Morse Auditorium
8701 Gracie Allen Drive
Los Angeles, California 90048
United States

Map and Directions
Sponsored by Samuel Oschin Comprehensive Cancer Institute

 Click Here to view the conference brochure!   

Course Description and Statement of Need

This third annual educational activity will provide guidance to front-line clinicians, nurses, nurse practitioners, physician assistants, and pharmacists with the most current information available about new agents in oncology and the translation of the latest research to their patients. Experimental Therapeutics in Oncology: The Road to Personalized Medicine (3rd Annual Symposia) will cover drug and treatment updates with a focus on new agents in ovarian cancer, myeloma, head and neck cancers, renal cancer and hematological malignancies. In addition, renowned faculty will present lectures on common abnormal pathways targeted in treatment and profile the pharmacokinetics of new drugs. On the second day of the conference, a special mini-session on melanoma will also be offeredfollowed by the keynote address on the 6th vital sign.

Target Audience

This educational activity is intended for primary care and oncology clinicians, oncology nurses, physicians, pharmacists, nurse practitioners, physician assistants, and for other healthcare professionals involved in the care of patients with cancers.

Educational Objectives     

  • Identify the challenges and logistics of recommending, dispensing and managing side effects for new targeted drugs in oncology.
  • Describe and recognize the important pathways that are altered during malignant transformation.

  • Indicate the importance of identification of abnormal targets for best treatment choice.

  • Evaluate the importance and necessity of pharmacokinetic studies in clinical trials.

  • List the new clinical study results that led to the approval of new therapies for cancer treatment.

  • Identify the new potential biomarkers used for screening patients for targeted therapy.

  • Describe the antitumor efficacy and the indication of use of antiangiogenic drugs for treatment of gynecologic malignancies.

  • Recognize and describe the mechanism of action, efficacy and side-effects of new treatment options for myeloma.

  • Identify the methods used to identify patient susceptibility to cancer treatment.

  • List and apply new treatment options for head and neck cancer.

  • List and apply new treatment options forrenal cancer.

  • List and apply new treatment methods and new targeted therapies for hematological malignancies.


Accreditation Statement
Cedars-Sinai Medical Center is accredited by the Accreditation Council for Continuing MedicalEducation to provide continuing medical education for physicians.

Credit Designation Statement
Cedars-Sinai Medical Center designates this live activity for a maximum of 9.5 AMA PRACategory 1 Credits™. Physicians should claim only the credit commensurate with the extent oftheir participation in the activity.

The California State Board of Registered Nursing accepts courses approved by the ACCME forcategory 1 credit as meeting the continuing education requirements for license renewal.

Self-parking is available in the visitor parking lots P1, P2 (George Burns Road), or P4 (Sherbourne Drive).

Hotel Accomodations
For a list of local hotels that offer exclusive rates to Cedars-Sinai Medical Center, please click here.  Please be sure to mention that you are attending a course at the medical center to ensure you get the best rate.


Contact Information

Payment Instructions

  • If you prefer to pay by check, please download the registration form by clicking here.
© 2019
Quick, easy and affordable online event registration and event management software for all event sizes.